Our US and global expertise allows us to provide comprehensive, strategic solutions to your pricing and reimbursement challenges, boosted by a uniquely efficient form of agile stakeholder validation that informs and enhances decision-making.
Reinforced by an in-depth knowledge of the application and methodologies of US market access analytics, our integrated approach also draws support from our wider RWE and HEOR capabilities as required.
Direct stakeholder engagement is critical when assessing your access and pricing strategy, insights, and messaging. Supported by our experts, our online RPR platform leverages a global network of 3,500+ vetted stakeholders across 65+ countries to secure robust insights in a fraction of the time and cost of a traditional approach.
The RPR platform integrates real-world insights from decision-makers, enriching research findings and bridging data gaps to align with research goals.
RPR not only fills research gaps but also refines insight. For instance, while secondary research might hint at a need for more RWE, RPR pinpoints the methodologies and outcomes acceptable to payers.
RPR dives deeper than traditional research, sourcing data directly from key audiences, including payers, physicians, KOLs, and patient advocacy groups.
Manufacturers can fine-tune their market access and pricing strategies with RPR, enabling precise decision-making and clear identification of both risks and opportunities.
Supported by specialist teams, our suite of agile technology platforms allows us to provide clients with enhanced pricing and market access services by delivering impactful insights at an accelerated rate.
Our RPR platform can be employed to integrate stakeholder insights into any aspect of product development and commercialization. EVID AI enhances and accelerates literature reviews; Dashboards leverage data visualization techniques to transform and extrapolate value from complex data into communicable insights; and our Integrated Evidence Planning platforms meet the challenge of evidence organization and communication.
We search the globe for the most reputable experts before vetting them for suitability through a rigorous quality assurance and testing procedure. Each expert is tagged and classified according to their area of expertise and location, so that we can match the right experts to the right research objectives for our clients.
If you are an experienced healthcare decision-maker/stakeholder interested in helping to optimize patient outcomes, we invite you to consider sharing your expertise via our online survey platform, providing input when your schedule allows and being remunerated for your time.
A World EPA Congress 2024 presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group.
With more and more innovative vaccines and immunization strategies coming to the market, there is an increasing drive for understanding the key decision drivers for vaccine market access. However, the overall decision-making processes across markets are often ill-defined.
Through our proprietary RPR platform, we have engaged with key decision stakeholders in vaccine market access to ‘shine a light’ on key decision criteria and access processes for vaccines in order to evaluate the opportunities of novel vaccines and guide strategic market access decisions.
Your access and pricing needs can be met through our optional FIT engagement model, an innovative approach which provides dedicated, cross-functional RWE, HEOR, and market access teams that integrate seamlessly within your own to fill experience gaps or supplement existing resources.
The size and composition of your team can gradually evolve or pivot quickly to meet your changing needs, all without the costly delays involved in adjusting a statement of work.
A trusted extension of your organization, our team becomes your team.
Our teams have co-authored over 1000 publications across the full range of therapeutic areas, data sources, indications, and methods. A selection of our recent access and pricing related publications can be found below. For a wider list, please visit our publications directory.
| Title | GR Author(s) | Year | Therapeutic Area | Data Source | Journal/Conference | Full Citation & Links |
|---|---|---|---|---|---|---|
| Assessment of the relevance and credibility of indirect treatment comparisons to help inform health technology assessment and reimbursement decision-making: results of a 5-country payer survey. | Katsoulis I, Graham A | 2023 | General Medicine | RPR Survey | ISPOR Europe | View |
| Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment in Oncology. | Ignjatovic T | 2023 | Oncology | RPR Survey | ISPOR Europe | View |
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
